More interesting news coming our way from the American Heart Association 2006 Scientific Sessions in Chicago. Research done by the University of Rochester Medical Center shows that Rheos™ Baroreflex Hypertension Therapy™ System, a product of CVRx®, Inc., shows promise for drug resistant hypertensives. As we have previously reported, the investigational device by a Minneapolis, MN company functions through activation of carotid baroreceptors, and is implanted surgically.
Here’s what University of Rochester says about its research:
The trial is designed to assess device safety and efficacy in patients with systolic blood pressure of 160 mmHg or greater, despite being on at least three anti-hypertension medications, including one diuretic. The presentation reported on the first 10 U.S. patients enrolled in the trial. After one month of surgical recovery, baseline blood pressure was assessed and the device was activated. Three months of active Rheos therapy reduced systolic blood pressure by an average of 22 mmHg (180 mmHg vs. 158 mmHg) and diastolic blood pressure by an average of 18 mmHg (105 mmHg vs. 87 mmHg), using office cuff measurements. The implants were well tolerated and there were no unanticipated serious adverse events related to the system or procedure.